Abstract

) The present program grant application concerns the use of a synthetic peptide (802-2 peptide) in clinical trials and the further development of modifications of the peptide treatment. As such, the proposed research of all projects in this program involves extensive use of synthetic peptides and the success of the program depends on the availability of high quality peptide materials. In this regard, the peptide synthesis core will be vital in providing these synthetic materials for each of the projects. In addition, it is expected that the core leader's experience with the design, synthesis, and study of chemical modifications to improve peptide activity and stability will allow the core to serve as an interactive resource for translating hypotheses about peptide structure and function into potential therapeutic agents and experimental design for testing their effects on T cell function.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA077401-03
Application #
6446911
Study Section
Subcommittee G - Education (NCI)
Project Start
2001-04-11
Project End
2003-03-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
3
Fiscal Year
2001
Total Cost
$196,218
Indirect Cost

  Institution

Name
Thomas Jefferson University
Department
Type
DUNS #
061197161
City
Philadelphia
State
PA
Country
United States
Zip Code
19107

  Publications

Varadi, Gabor; Friedman, Thea M; Korngold, Robert (2005) A CD4 domain 1 CC' loop peptide analogue enhances engraftment in a murine model of bone marrow transplantation with sublethal conditioning. Biol Blood Marrow Transplant 11:979-87
Loza, Matthew J; Perussia, Bice (2004) Differential regulation of NK cell proliferation by type I and type II IFN. Int Immunol 16:23-32
Deguchi, Masatoshi; Whitaker-Menezes, Diana; Jones, Stephen C et al. (2003) 12E2: a cloned murine dermal cell with features of dermal dendrocytes and capacity to produce pathologic changes resembling early Kaposi's sarcoma. Am J Pathol 163:1817-25
Loza, Matthew J; Perussia, Bice (2003) Accumulation of type 2 cytokine+ T cells: differentiation-independent proliferation of pre-existing type 2 T cells. Eur J Immunol 33:939-49
Loza, Matthew J; Perussia, Bice (2002) Peripheral immature CD2-/low T cell development from type 2 to type 1 cytokine production. J Immunol 169:3061-8
Loza, Matthew J; Peters, Stephen P; Zangrilli, James G et al. (2002) Distinction between IL-13+ and IFN-gamma+ natural killer cells and regulation of their pool size by IL-4. Eur J Immunol 32:413-23
Hsieh, Michael H; Varadi, Gabor; Flomenberg, Neal et al. (2002) Leucyl-leucine methyl ester-treated haploidentical donor lymphocyte infusions can mediate graft-versus-leukemia activity with minimal graft-versus-host disease risk. Biol Blood Marrow Transplant 8:303-15
Kim, Judith C; Whitaker-Menezes, Diana; Deguchi, Masatoshi et al. (2002) Novel expression of vascular cell adhesion molecule-1 (CD106) by squamous epithelium in experimental acute graft-versus-host disease. Am J Pathol 161:763-70
Loza, Matthew J; Metelitsa, Leonid S; Perussia, Bice (2002) NKT and T cells: coordinate regulation of NK-like phenotype and cytokine production. Eur J Immunol 32:3453-62
Azzoni, Livio; Papasavvas, Emmanouil; Chehimi, Jihed et al. (2002) Sustained impairment of IFN-gamma secretion in suppressed HIV-infected patients despite mature NK cell recovery: evidence for a defective reconstitution of innate immunity. J Immunol 168:5764-70

Showing the most recent 10 out of 11 publications